NCT00543634View on ClinicalTrials.gov

Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Postmenopause
Interventions
DRUG

Premarin/MPA

0.625 mg/2.5 mg X4

DRUG

Premarin/MPA

0.625 mg/5 mg X 2

DRUG

Provera 10 mg

2.5 mg of MPA, 4 tablets dissoved in water

Trial Locations (1)

68154

Omaha

Sponsors

Collaborators (1)

MDS Pharma Services
All Listed Sponsors
collaborator

MDS Pharma Services

INDUSTRY

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00543634 - Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women | Biotech Hunter | Biotech Hunter